morning, joining strong and position doing our of you, closing in a well in and is operations. Thank growth, portfolio XXXX financial thanks and Ligand business I Good our am in to that for excellence Patrick. is report pleased expansion call. terms
to partners, supporting our secondly, and helping their first There their I’d some simple and our to helping partners go our of technology. medicines. have safety the like serve We our delivering helping our serve X industry. reduce Ligand but the with We major Slide with to medicines, them partners is their several start are we program to to slide, today. turn new A cost improve that slides is discover medicines, how are make out. thirdly value. research We
technologists. are We
what world. are help We proud doing the in care we are to innovators, human health around and are we the facilitate of
are are Slide the and third in strong and quarter business short-term. Let’s would news was our comments in patient Kyprolis a the for we QX very board. posted financial major X. Both pleased we and particular, across the our year. M&A about major of underlying start specifically. give to are on but revenue increasing some impact XXXX. in quarter Amgen to and visits highlights, we exceptional relapsed I’d and discussed, indications overall regions, treatment over products pandemic combined as label portfolio to this earlier myeloma performance. to launch all like assets royalty-bearing forecasted QX turn the some and regimen with DARZALEX an Earlier also major But in recently with pleased early growth now, returning following see positive we point noted that multiple data year, for the expansion of very growth QX
Notably, before expanding we a approval and five be to our Now entitled have into productive with have than partnered development had drugs a to programs to in in more we up is Ligand with partners. in five entering to projected top-tier terms year-to-date portfolio, for alone. of where XXXX we’ve M&A completed bringing granting royalty now Ligand partners ever recently license new contracts transactions our rights multiple very technology
proud illustrated for need business a Captisol world’s One, partnership remdesivir, the For very manufacture best meet remdesivir. to operations, it’s our excellence of. Gilead by production the to with in up ability scale supply are we it’s of rapidly our Captisol
or approved company only for Captisol in the the the FDA record provides branded the will standard-of-care. armamentarium, Our the We safety approved other to part a is be society the works considered add know Veklury to is make need for and drug back we this vaccines. required the to this other U.S. the eventually first treatment today to vital quantity, COVID-XX. to quality, and of is purity, normal, now is for ingredient. get it. and treatments be need but No There treatments we
As arm. remdesivir decreased, COVID-XX U.S. control to rate the in note, will be trials thanks of Surgeon go the the therapeutic country to to use has factors such, are while clinical up, mortality all last Of Friday including the required and remdesivir. starting that General hospitalizations current future said, just multiple use
team FDA now XX% fully On and percentages seen have their of appropriate the controlled grow clinical that pinnacle clinical trial that executive are five global hospitalized have clinical Veklury Gilead a hospital been are people to They clinical the getting past options today. that remarked they randomized they Gilead to and the working in U.S. in pure under estimate patients Gilead in They Veklury to potentially an demonstrated from said unequivocally of powered, field studies recent now in in approval. average of receiving review across peer see XX% trials physicians these expand reduction days. trials. the how They call, trials and that Recent the live the also showed said educate trials. hospital setting. clinical best determine publications definitive Veklury of recovery that population they currently from earnings of is roughly The to right of placebo-controlled, Also benefits the expected results an of benefits they being repeatedly with patients the science on have time as the commented multiple a use data double-blind, to blinded the review note, also quarter, reminded drug additional outside Veklury. the on treatment use patient outpatient
Ligand, highly Captisol their As for is with meet clear work our not for to could Gilead need that needs. the Ligand, real remdesivir interactive to and more be given
of forecast adding of and third we revenue XXXX contribution can year this total the making revenue revenue next year, year. adding We we international their that significantly million Gilead Captisol and about consortium. see alone, is this This it’s $XX our at about possibly supply of for as a time in generics at not as we to had contemplated it much this are supply start more
and major medical is again markets worldwide We patients now pandemic also drive this drug are benefit the skyrocketing. to know, reinforce demand but raging hospital and not remdesivir, right from how all will much can for will think now. healthcare system right this rates only we As the
value we on additional investors. Our based no doubt selling and benefit the to our support and our are for Captisol But growth proposition is business upside, project. core is strategic Ligand our we and long-term financial remdesivir driving
the in inbound We all this our ingredient as are to better supply answering manufacturing at for given short-term an off as Captisol request time are well, in now high. the success key call
support partners about novel allow in Ligand’s come for other came working COVID-XX, support us first substantial that medical business Captisol months with that business drive to partners over from other there antiviral expanding from different a the treating and far to to along approved the platform. so market we derived in the on are antibodies treatment For and and novel three the needs next an antibodies treatments sales for also Ligand know future is have three COVID-XX Captisol the will Veklury for long-term pleased R&D are as different to we few invest we my next surge are pleased remdesivir for OmniAb the will forecast recruitment us further quarters, undoubtedly developing technology. only FDA and Along in COVID-XX, to comments enable to XX growth. the
a five potential switch like to on just highlight Slide have calendar for are next important that tied potential history deck main an events we some to recently. year. the X and approval events as high late-stage regulatory calendar had company This Chinese well-funded, some in of while largest programs I’d our and to One with news we Now, of had clinical CSTONE, well. is major approvals significant the science that’s programs. This partnered is very news is
Alvogen Merck the and – now and Notably, Alvogen. of three Gloria of with Jazz of with and Pfenex. our another Jazz with are acquisition this Merck, these programs came them, partnership via have with towards OmniAB-based programs two with We
bid business We about is The entered next major contracts about very OmniAB market streams Ligand’s lung are that of these and our get derived There as is note the for form partnering for basis is royalties. taken examples potential have of derived into up commercial starting from to our CSTONE patients technology pleased out variety the and positive these rate the one doing partner our a to cancers. reducing in trial, are leading and and call antibody will above programs, well the their create perform the up continues death trial on given data concluded a new for readout program cancer. OmniAB a CSTONE they many calendar stock the to us for Picking are value. for rare of billion see outstanding year. number comment Investors royalty interim quick the to but develop excited CSTONE’s this commercial rights we’ll The and an assets highlight development recent platform. early results the is to $X expectations. on one This the
as a Pfizer major $XXX collaboration including a between collaboration with More investment encompasses and deal formation companies million the importantly, major pharma that two first a the The We the worth calling have CSTONE commercialization CSTONE cell CSTONE a for million out recently as and deals signature a is CSTONE. to with struck discovered companies, Pfizer of major Ligand be antibody in for line find squamous announced $XXX strategic of validation cancer. but treatment for events in financial antibody. important this CSTONE’s four an It’s deal lung bellwether non-small non-squamous a category. major Ligand-based Stage of for a
trial multi-center performance Xa antibody. a market derived being due pursuing announced to the Immunovant’s Another Ligand-based trial half this antibody Immunovant, for that also and $X lead as billion, has antibody. first –that’s Phase program example to This success was a a cap an developing used an of injection again for is from They in Immunovant largely registration-enabling gravis. antibody. Phase with form of subcutaneous OmniAB’s myasthenia stellar their which X patients placebo-controlled the is their OmniAB of positive grown XXXX. It’s results top-line is are now
financial acquisition on be comment weeks year deal. on that Ligand. our profitability. a we Pfenex looking see quick at Pfenex revenue Just growth a we’re Ligand great short the it but deal next for acquired meaningfully Matt color that through provide few to just since assets based will a going both Pfenex it and proven in deal. transformative of since these Foehr acquisition, the three approvals we to add our in that more to has is We about project are as closed to
business revenue Our our the next and main by to revenue out as about few is boost look Pfenex we for royalty years. projected to is driver royalty XX% our
supporting last projects Slide given provided to business to going the over from spend additional earnings This growth up revenue. for Overall, royalty for well should forward. wrap licensing PSA multiple flows growth XXXX. acquisition, not outlook so parties keep and and we and is in adjusted make This in right about Analyst discussions investing I’d committed strong and for We’ve see just we growth year to high top-tier other profit guidance for per growth at Alright, and and changing over our like XX, top-line XX% the the internal business. we cash to than Captisol growth In years R&D viewed up, protein the XXXX by CE-Iohexol. go as our far, see with are proprietary over remain are as and our these This backed expression calling as XXXX from in more XXXX. our share diluted we operations existing having growth last our bottom-line year-over-year. earnings Day the programs, X increases I as come. The and XX% near-terms sharply revenues we our and value information gained over over partners platform addition, we now Ligand. coming strong forecasting funding just of big the Funding to promising accelerating right remarks two some is we Pfenex annual in is as now, year long-term lean which in assumes ability robust week outlook for are be have now
review a guidance, the financial our more call over detailed of and Now, Matt like to Korenberg. to for I’d turn results
